News

REGENXBIO initiates a pivotal trial for surabgene lomparvovec, aiming to transform diabetic retinopathy treatment and improve patient outcomes.

Sandoz will hold exclusive or semi-exclusive marketing rights in several European and Asian countries

New research findings reveal that increased physical activity significantly slows visual field loss in patients with glaucoma, highlighting exercise as a potential protective factor.

PA5108 is a rod-shaped, biodegradable microimplant designed to significantly reduce IOP in patients with primary open-angle glaucoma consistently over 6 months.

AAVB-039 is the company’s gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4.

Ocular salvage and preservation of vision are essentially dependent on early diagnosis, and several studies have been conducted to identify the factors leading to delayed diagnosis at presentation.

An ophthalmologic examination revealed bilateral anterior uveitis, though the patient had no ocular complaints at presentation

João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases

Tirzepatide and semaglutide show favorable ocular safety compared to traditional weight loss formulations

NICE approves idebenone for Leber hereditary optic neuropathy, offering hope for vision restoration and improved quality of life for patients.

Catch up on this week's highlights in retina.

In a press release, the National Institute for Health and Care Excellence announced the first-ever approval for a mitochondrial disease treatment.

Franklin shares how methotrexate significantly reduces reoperation rates in diabetic patients with retinal detachments, enhancing postoperative outcomes and vision.

4D Molecular Therapeutics showcases promising SPECTRA trial results for 4D-150, highlighting its potential to revolutionize diabetic macular edema treatment.

The transaction is anticipated to close in 6 to 12 months subject to customary closing conditions and regulatory approval

New findings confirm TearCare's long-term effectiveness for dry eye disease, showing significant patient improvements with minimal treatments over 2 years.

In a press release, the National Institute for Health and Care Excellence announced the first-ever approval for a mitochondrial disease treatment

Survey reveals severe impact of Good Days underfunding on retina practices, with many patients experiencing vision loss due to delayed access to care.

The DAVIO-2 study reveals EYP-1901's potential as a 6-month treatment for neovascular AMD, matching aflibercept's vision outcomes with fewer doses.

New research identifies key factors influencing visual recovery in Leber hereditary optic neuropathy patients treated with gene therapy, enhancing treatment strategies.